Richard S. Finn
University of California, Los Angeles(US)University of Santa Monica(US)
Publications by Year
Research Areas
Hepatocellular Carcinoma Treatment and Prognosis, Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research, Cancer Immunotherapy and Biomarkers, Pancreatic and Hepatic Oncology Research
Most-Cited Works
- → Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma(2020)6,907 cited
- → Hepatocellular carcinoma(2021)6,190 cited
- → Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial(2018)5,304 cited
- → Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases(2018)4,515 cited
- → AASLD guidelines for the treatment of hepatocellular carcinoma(2017)4,115 cited
- → Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial(2016)3,612 cited